IRON · Disc Medicine, Inc.

The thesis

Disc Medicine's lead drug, bitopertin, passed its Phase 3 APOLLO trial on 19 October 2026. That result answers the reason the Food and Drug Administration (FDA) rejected the drug in February, which makes the shares modestly more likely than not to beat the S&P 500 over the next three months. The case depends on the company resubmitting the new drug application (NDA) by the end of 2026, as it has guided, and on its other blood-disorder programs at the American Society of Hematology (ASH) meeting on 12 December to 15 December 2026.

The FDA issued a complete response letter (CRL) on 13 February 2026. Press coverage of the letter reported that the agency accepted that bitopertin lowers protoporphyrin IX (PPIX), the toxic metabolite that drives erythropoietic protoporphyria (EPP), a rare disease that makes sunlight painful. The agency did not accept that the drop predicts clinical benefit, and it asked for a further trial. APOLLO measured that benefit directly. It enrolled 183 patients and cut PPIX by 41.4% against placebo (p<0.0001). It added 12.2 hours a month of time in light without pain (p=0.0010), and every secondary endpoint was met, according to the company's 19 October 2026 release.

The company expects an FDA decision by mid-2027. The rating is MEDIUM because the main question from the February letter now has a direct answer, while a funding overhang and a rally that is already large keep the probability well short of high. At the $87.08 close on 11 November 2026, the shares sit 12.5% below the $99.50 intraday high of 8 December 2025, set before the rejection. On that gap, the price already credits most of the approval odds the shares lost in February.

Bullish and bearish views on Disc Medicine, Inc.

The bull case on Disc Medicine, Inc. (IRON), in brief: APOLLO answers the FDA's stated objection. The bear case: New shares keep coming to market.

Bull case

• APOLLO answers the FDA's stated objection. The CRL asked for proof that the PPIX drop means real benefit for patients. APOLLO showed a 12.2-hour monthly gain in pain-free light exposure against placebo (company release, 19 October 2026), and coverage of the letter reported no manufacturing issues were raised.
• Funding runs into 2030. Cash, equivalents and marketable securities were $682.8 million on 30 September 2026, before the October offering. The company says its cash plus the offering's proceeds fund operations into 2030 (third-quarter report, 5 November 2026).
• Two more programs report at ASH. Updated selcodebart data in anemia of myelofibrosis, along with polycythemia vera and sickle cell data for DISC-3405, will be presented at ASH from 12 December 2026 (company release, 4 November 2026). The company also expects FDA feedback on a pivotal selcodebart plan by the end of 2026.
• Analyst targets moved up after the report. Guggenheim started coverage with a Buy rating and a $132 target on 9 November 2026. HC Wainwright raised its target to $127 on 6 November 2026.
• Losses narrowed. The third-quarter net loss was $59.5 million, or $1.53 a share, against $62.3 million a year earlier. The loss per share beat the $1.76 consensus estimate (5 November 2026).

Bear case

• New shares keep coming to market. The company priced 6,000,000 shares at $75.00 on 21 October 2026 for $450 million gross. On 5 November 2026 it filed an at-the-market sales agreement with TD Cowen for up to $189.93 million more, which can add supply into any rally.
• Directors and officers have sold steadily. SEC Form 4 filings show director Kevin Bitterman sold 41,825 shares at an average of $80.13 between 19 October 2026 and 21 October 2026 under a Rule 10b5-1 plan. Chief Executive Officer John Quisel sold 33,000 shares at an average of $79.15 on 17 August 2026 under such a plan.
• Tolerability could shape the label. Dizziness was the most common adverse event in APOLLO, reported in 50% of patients, mostly mild or moderate, according to the third-quarter update of 5 November 2026.
• The approval is still months away. The company guides to an FDA decision by mid-2027, past the three-month window. A gain in the shares before then depends on filing milestones and pipeline data.

Price setup

The shares closed at $87.08 on 11 November 2026, their third straight higher close after $78.91 on 6 November 2026. As of 11 November 2026, the 50-day moving average is $71.52 and the 200-day moving average is $70.93. The last close sits well above both.

The 52-week closing low is $55.74, set on 14 October 2026, five sessions before the APOLLO results. The 52-week intraday high is $99.50, set on 8 December 2025. The 3-month change is 8.8%, measured from the $80.01 close on 13 August 2026. The $75.00 October offering price is the level at which institutions took the largest block of new stock.

The $99.50 high marks where the market priced bitopertin before the rejection. A move back toward it would mean the market treats the resubmission as close to a full reversal of the February letter.

Catalysts ahead

• 12 December 2026: 68th ASH Annual Meeting (12 December to 15 December 2026): selcodebart RALLY-MF update, DISC-3405 polycythemia vera and sickle cell data. Shows whether the pipeline behind bitopertin holds up, which matters for value beyond a single EPP approval.
• ~31 December 2026 (est.): Bitopertin NDA resubmission to the FDA, guided for the end of 2026. Filing on time keeps the mid-2027 decision on track; the FDA's acknowledgment and goal date then set the review clock.
• ~31 December 2026 (est.): Selcodebart End-of-Phase 2 FDA feedback and pivotal plan for anemia of myelofibrosis. Sets whether a second program moves into a registration trial in 2027.
• ~30 June 2027 (est.): Expected FDA decision on resubmitted bitopertin NDA (mid-2027 per company). Approval would make Disc Medicine a commercial company; a second rejection would remove most of the case.

What would change the view

A daily close below $78.47, the 5 November 2026 close on the day of the third-quarter report and the at-the-market filing, which would erase the post-report gains; or no bitopertin NDA resubmission announced by 31 December 2026.

The risks this note tracks, each with what would confirm it:

• The bitopertin resubmission slips past the guided end-2026 timing. Confirmed by: No company announcement of the NDA resubmission by 31 December 2026.
• The FDA sets a review goal later than mid-2027 or raises new questions on the resubmitted application. Confirmed by: A company disclosure of an FDA action date after 30 June 2027 or of an advisory committee meeting.
• Share sales under the TD Cowen at-the-market program dilute holders and cap rallies. Confirmed by: ATM proceeds or a higher share count reported in the 2026 10-K.
• Dizziness, reported in 50% of APOLLO patients, leads to a restrictive label or weak uptake. Confirmed by: FDA labeling discussions or full APOLLO data showing discontinuations tied to dizziness.
• Pipeline data at ASH disappoint and the market reprices the non-bitopertin programs. Confirmed by: Updated RALLY-MF or RESTORE-PV data at ASH from 12 December 2026 showing weaker responses than earlier cohorts.

What it trades with

Disc Medicine's shares trade mainly on the company's own regulatory and trial dates. The 19 October 2026 APOLLO result and the 13 February 2026 rejection drove the largest moves of the past year. Between those dates, the shares tend to track small- and mid-cap biotech sentiment. Companies in the same rare-disease group (Viridian Therapeutics, Xeris Biopharma, Septerna, Delcath) report on unrelated assets, so their own results carry little information about bitopertin's review.

Headlines tagged with the IRON ticker about Ironveld plc, a UK-listed miner, appeared in late October and early November 2026. They concern a different company.